Cytek (CTKB) Q2 2026 earnings review
Top-Line Stability Overshadowed by Bleeding Operating Margins
Cytek delivered a Stable 6% YoY revenue growth in Q2 2026, driven by a reliable recurring revenue engine and a rebound in U.S. and China instrument sales. However, this top-line resilience failed to translate into earnings. Net loss more than doubled YoY to $12.2 million, and Adjusted EBITDA flipped negative as the company buckled under a 24% surge in General & Administrative expenses tied to litigation and severance. While management marginally raised its full-year revenue guide, the underlying margin profile—propped up this quarter by a one-time tariff refund—paints a bearish picture of profitability.
🐂 Bull Case
Service and reagent revenues continue to act as a highly predictable growth engine, reaching $18.5M in Q2 and now comprising 35% of total trailing-12-month revenue. The installed base expanded by a healthy 142 units.
After a volatile 2025 and Q1 2026, product revenue grew year-over-year driven by strong demand in the U.S. and China, proving the core FSP technology remains competitive.
🐻 Bear Case
G&A expenses surged 24% YoY to $16.8M, primarily due to ongoing patent litigation and severance costs. This structural overhead is actively preventing revenue growth from flowing to the bottom line.
Reported GAAP gross margin of 59% looks impressive until adjusted for a one-time tariff refund. Excluding this, GAAP gross margin was 53%—flat/down compared to previous quarters despite higher volumes.
⚖️ Verdict: 🔴
Bearish. Reliable recurring revenue growth cannot hide the severe degradation in operating leverage. Until the litigation expenses subside and clean gross margins show organic expansion, the earnings profile remains highly problematic.
Key Themes
Recurring Revenue Momentum
Accelerating. Cytek's strategic shift toward a razor-and-blade model is working. Total recurring revenue (services and reagents) reached $18.5 million in Q2. The installed base grew by 142 units to 3,933, expanding the captive funnel that drives this high-margin recurring stream. On a trailing-12-month basis, recurring revenue now represents 35% of total sales, up from 32% a year ago.
G&A and Litigation Drag
Decelerating sequentially but severely elevated YoY. General and administrative expenses reached $16.8M, a 24% YoY increase. While this is an improvement from the $18.5M shock in 26Q1, the sustained burden of patent litigation and severance costs is structurally impairing Cytek's ability to generate positive EBITDA. Management's inability to cap these expenses is a primary risk.
Underlying Gross Margin Weakness
Stable to slightly Decelerating. Management reported a GAAP gross margin of 59%, a massive apparent jump from 52% a year ago. However, this narrative is misleading. Excluding a one-time tariff refund, GAAP gross margin was actually 53%, and adjusted gross margin was 56%. This reveals that core manufacturing and service delivery margins are barely treading water despite top-line growth.
U.S. and China Instrument Rebound
Reversing. Product revenue grew to $32.6M from $31.4M a year ago, explicitly driven by strong instrument growth in the U.S. and China. This reverses the severe geographic headwinds (specifically in APAC and U.S. academia) cited in prior quarters and proves end-market demand for Cytek's hardware is stabilizing.
Innovation Pipeline Maturing
Cytek launched two major hardware updates: the Cytek Borealis, a 7-laser full spectrum flow cytometer capable of 60-color panels, and new Aurora Evo configurations designed for highly automated lab environments. These launches directly target the high-throughput biopharma space, aiming to drive premium hardware ASPs while locking in proprietary reagent usage.
Macro Environment and Tariffs
Tariffs continue to act as a wild card for the life sciences tools sector. While Cytek clawed back margins this quarter via a tariff refund, the underlying global trade friction remains. The company's reliance on China for hardware growth leaves it uniquely exposed to geopolitical shifts and future export control changes.
Other KPIs
Stable. The balance sheet remains Cytek's strongest asset. Despite burning through a $12.2M net loss in Q2, total liquidity only decreased by $0.2M sequentially from Q1 ($262.2M). This implies solid working capital management and provides a massive runway to endure the current cycle of elevated litigation expenses.
Accelerating YoY (+15%). Operating expense growth vastly outpaced revenue growth (+6%), driven heavily by G&A. Until OpEx growth decelerates beneath revenue growth, Cytek will remain locked in an operating loss position.
Guidance
Stable. Management raised the midpoint of the FY26 guidance by $1M to $209.5M. Compared to FY25 actuals of $201.5M, this implies an annual growth rate of roughly 4.0%. This suggests that the 6% YoY growth seen in H1 2026 will decelerate slightly into the back half of the year.
Key Questions
Structural Gross Margin Trajectory
The one-time tariff refund artificially boosted Q2 gross margins to 59%. What is the structural gross margin expectation for H2 2026 once this benefit rolls off, and how are rising service labor costs impacting that?
Litigation Expense Visibility
G&A expenses remain highly elevated due to ongoing patent litigation. Can management provide a timeline or a quarterly spending cap on expected legal expenses for the remainder of FY26?
China Demand Sustainability
You highlighted strong instrument growth in China this quarter. Given the broader macro weakness and order timing volatility seen in the region historically, how sustainable is this localized demand through the end of the year?